Article Per Year (5 Year)
p-Index From 2020 - 2025
0.23
P-Index
This Author published in this journals
All Journal Jurnal Biomedika dan Kesehatan Cermin Dunia Kedokteran
Utami, Desak Nyoman Trisepti
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Health Professions Immunology & microbiology Medicine & Pharmacology Public Health

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Disfungsi Sawar Epidermis dan Strategi Penanganan Dermatitis Atopik Utami, Desak Nyoman Trisepti
Cermin Dunia Kedokteran Vol 41, No 4 (2014): Dermatologi
Publisher : PT. Kalbe Farma Tbk.

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (1064.563 KB) | DOI: 10.55175/cdk.v41i4.1145

Abstract

Dermatitis atopik (DA) merupakan penyakit kompleks yang mengenai sampai 20% anak-anak dan berpengaruh besar pada kualitas hidup pasien dan keluarganya. Pengetahuan baru tentang patofisiologi DA menekankan pada peranan penting kerusakan struktur epidermis dan disregulasi imun. Filaggrin (FLG) mempunyai peranan penting pada sawar epidermis dan mutasi FLG menyebabkan gangguan fungsi epidermis. Gangguan sawar membuat kulit lebih permeabel terhadap iritan, alergen dan mikroorganisme. Terapi DA bertujuan untuk mengontrol rasa gatal, menekan inflamasi, dan mengembalikan sawar kulit.Atopic dermatitis (AD) is a complex disease that affects up to 20% of children and impacts the quality of patients and families in a significant man¬ner. New insights into the pathophysiology of AD point to an important role of structural abnormalities in the epidermis combined with immune dys¬regulation. Filaggrin (FLG) plays a critical role in the epidermal barrier, and FLG mutations cause abnormal epidermal function. Barrier abnormalities render the skin more permeable to irritants, allergens, and microorganisms. Treatment of atopic dermatitis must be directed to control the itching, suppress the inflammation, and restore the skin barrier.
Keefektifan Injeksi Toksin Botulinum Tipe A (BTX-A) untuk Terapi Neuralgia Pasca Herpes: Sebuah Tinjauan Pustaka Wijaya, Edward; Winaya, Ketut Kwartantaya; Utami, Desak Nyoman Trisepti
Jurnal Biomedika dan Kesehatan Vol 8 No 1 (2025)
Publisher : Fakultas Kedokteran Universitas Trisakti

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.18051/JBiomedKes.2025.v8.87-97

Abstract

Postherpetic neuralgia (PHN) is a common and debilitating complication of shingles, characterized by persistent pain that lasts for months to years after the resolution of the herpes zoster rash. While various treatments, such as anticonvulsants and opioids, are commonly used, they often fail to provide adequate pain relief and are associated with significant side effects. Botulinum toxin type A (BTX-A), traditionally used for muscle spasticity, has emerged as a promising treatment for PHN due to its ability to reduce pain through its neurotoxic effects. This literature review evaluates the safety and efficacy of BTX-A in treating PHN by reviewing 30 studies sourced from databases such as PubMed, Medline, and PubMed Central. The results indicate that BTX-A injections significantly alleviate PHN-associated pain, with many patients experiencing a reduction of up to 70% in pain severity. Additionally, BTX-A has been shown to improve patients' quality of life by enhancing sleep quality and reducing the need for oral medications. Although the results are promising, the review calls for further research to determine optimal dosing protocols and the long-term effects of BTX-A. Despite its limitations, BTX-A presents a potential therapeutic option for managing PHN, particularly for patients who do not respond well to traditional treatments.
Co-Authors Edward Wijaya, Edward Winaya, Ketut Kwartantaya